Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
NeuroGenesis Reports Positive Results from Phase 2 Study in Progressive Multiple Sclerosis
Details : NG-01 is a proprietary autologous bone marrow-derived stem cells designed to secrete high levels of remyelinating and neurotrophic factors at the CNS site of injury in multiple sclerosis.
Brand Name : NG-01
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 12, 2024
Lead Product(s) : Mesenchymal Stem Cells
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Hadassah Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results published in Stem Cells Translational Medicine show significant reduction of NF-L, a biomarker for neuronal damage, in patients with progressive multiple sclerosis after treatment with NG-01 stem cells.
Brand Name : NG-01
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 01, 2022
Lead Product(s) : Mesenchymal Stem Cells
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Hadassah Medical Center
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?